Camelot the Theme at This Year's CBCC Prom

This time of year means one very important thing to the teens who are part of the Hungry Bunch- the teen support group that operates out of the Children's Blood and Cancer Center at Dell Children's Hospital:

The Prom.

This year's theme was Camelot. Each year it's such an amazing event, and it doesn't happen without the tireless work of so many volunteers as well as the effort and contributions of its sponsors. This year was no different. The Prom is among the most anticipated nights of the year for the Hungry Bunch and for everyone involved in the CBCC, and it never fails to dazzle.

This is the 15th installment in my series on the Children's Blood and Cancer Center at Dell Children's Hospital in Austin, Texas. The prior thirteen are listed below:

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap